← Back to All Stocks

BDX - Becton, Dickinson and Company

In Value Zone (< 200W SMA)
Health Care
Dividend Aristocrat

Price History

About

Industry

Medical Instruments & Supplies

Employees

60,000

Headquarters

United States


Company Overview

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Price

$142.35

52-Week Range

$128 $187

Dividend Yield

2.95%

Dividend Score

B

Dividend

Yield 2.95%
Annual $4.20
Payout 73%
5Y Avg 1.64%

Valuation

P/E (TTM) 25.1
Fwd P/E 10.6
P/B 1.63
PEG 1.16

Profitability

Profit Margin 5.1%
Op Margin 14.7%
ROE 6.7%
ROA 4.4%

Financial Health

Current Ratio 0.94
Quick Ratio 0.36
Debt/Equity 72%

Cash Flow

Free CF $4.5B
Op CF $3.8B
Total Cash $816M

Performance (12M)

Price Change +3.23%
Total Return +6.26%

Analyst Consensus

Buy

14 analysts

Target: $183 $156 - $225
+28.8% implied

Annual Return Breakdown

Dividend Growth

Most Recent Annual Growth

7.19%

3-Year Avg Growth

6.03%

5-Year Avg Growth

5.96%

Annual Dividends

Year-over-Year Growth

Recent Dividend History

Ex-Dividend Date Amount
Mar 10, 2026 $1.0500
Dec 08, 2025 $0.8255
Sep 08, 2025 $0.8176
Jun 09, 2025 $0.8176
Mar 10, 2025 $0.8176
Dec 09, 2024 $0.8176
Sep 09, 2024 $0.7469
Jun 10, 2024 $0.7469
Mar 07, 2024 $0.7469
Dec 07, 2023 $0.7469
Sep 07, 2023 $0.7154
Jun 08, 2023 $0.7154
Mar 09, 2023 $0.7154
Dec 08, 2022 $0.7154
Sep 08, 2022 $0.6840
Jun 08, 2022 $0.6840
Mar 09, 2022 $0.6673
Dec 09, 2021 $0.6673
Sep 08, 2021 $0.6366
Jun 08, 2021 $0.6366